Disorder "Sickle Cell Anemia"
Found 352 records
Disorder information
Disorder name:
Sickle Cell Anemia 
Disoder ID:
OMIM entry:
Synonyms:
Hb SC disease,Hb-S/Hb-C disease,Hb-SS disease without crisis,Hemoglobin S disease without crisis,Sickle-cell/Hb-C disease without crisis,drepanocytosis,hemoglobin SC disease 
Definition:
Sickle cell anemias are chronic hemolytic diseases that may induce three types of acute accidents: severe anemia, severe bacterial infections, and ischemic vasoocclusive accidents (VOA) caused by sickle-shaped red blood cells obstructing small blood vessels and capillaries. Many diverse complications can occur. 
Modifier statisitcs
Record:
352 
Gene:
110 
Variant:
291 
Reference:
43 
Effect type:
Expressivity(325) ,Pleiotropy(22) ,Penetrance(4) ,Dominance(1)  
Modifier effect:
Risk factor(104) ,Altered HbF levels(76) ,Altered response to hydroxyurea(32) ,Altered HbF production(25) ,Altered severity(17) ,Bacteremia-prone phenotype(13) ,Altered white blood cell counts(11) ,Altered baseline HbF level(10) ,Altered hemoglobin level(9) ,Altered fetal hemoglobin (HbF) levels(8) ,Altered levels of fetalhemoglobin and pain crisis(8) ,Altered glomerular filtration rate(6) ,Altered stroke susceptibility(6) ,Altered anemia, leukocytosis, and thrombocytosis(4) ,Altered incidence(4) ,Altered level of Fetal hemoglobin(3) ,Altered levels of HbF(3) ,Altered susceptibility(2) ,Altered serum levels(2) ,Presence of albuminuria(2) ,Alter the occurrence of stroke(1) ,Altered HbF levele(1) ,Altered bilirubin level(1) ,Altered immune response(1) ,Altered level of fetal hemoglobin(1) ,Altered rate of hospitalization(1) ,Heterozygote susceptibility(1)  
Modifier gene Variant Effect type Modifier effect Evidence Effect PubMed ID
LCAT LCAT:rs7200210 Expressivity  Risk factor  P=0.024  A multiple regression model, which included age and baseline hemoglobin as covariates, retained SNPs in ACVRL1, BMP6, and ADRB1 as independently contributing to pHTN risk.more more
LAMA2 LAMA2:rs73599293 Expressivity  Altered white blood cell counts  P=0.00011  Associated with WBC(white blood cell) and ANC(absolute neutrophil count).more more
KLF1 KLF1:c.862A>T(p.Lys288*) Expressivity  Altered HbF levele  From review article  K288X mutation in KLF1 that disrupted the DNA-binding domain of KLF1, a key erythroid gene regulator.more more
KL KL:c.1109G>C(p.Cys370Ser) Expressivity  Altered HbF levels  Bayesian approach  Different genes might modulate the rate of decline of HbF and the final level of HbF levels in sickle cell anemia.more more
KL:c.1331-195A>G Expressivity  Risk factor  OR=1.59, 95% CI: (1.00 – 2.50), P= 0.0480  The SNPs in and near KL were associated with leg ulcers, as well as single nucleotide polymorphisms in candidate genes that could affect sickle vasoocclusion could be improved by agents that reduce sickle erythrocyte density or increase NO bioavailability.more more
KL:c.2247T>C(p.Ala749Ala) Expressivity  Altered HbF levels  Bayesian approach  Different genes might modulate the rate of decline of HbF and the final level of HbF levels in sickle cell anemia.more more
KL:c.-2927A>C Expressivity  Altered HbF levels  Bayesian approach  Different genes might modulate the rate of decline of HbF and the final level of HbF levels in sickle cell anemia.more more
KL:c.819+8880T>C Expressivity  Risk factor  OR=1.76, 95% CI: (1.16 – 2.66), P= 0.0076  The SNPs in and near KL were associated with leg ulcers, as well as single nucleotide polymorphisms in candidate genes that could affect sickle vasoocclusion could be improved by agents that reduce sickle erythrocyte density or increase NO bioavailability.more more
KL:c.820-14772G>A Expressivity  Altered HbF levels  Bayesian approach  Different genes might modulate the rate of decline of HbF and the final level of HbF levels in sickle cell anemia.more more
KL:c.820-14772G>A Expressivity  Risk factor  OR=1.56 (1.08 – 2.26), P= 0.0186  The SNPs in and near KL were associated with leg ulcers, as well as single nucleotide polymorphisms in candidate genes that could affect sickle vasoocclusion could be improved by agents that reduce sickle erythrocyte density or increase NO bioavailability.more more
Total 352,Each Page
,Jump To
Page